Spectra Clinical Laboratory

Summary Statement of Deficiencies D0000 A proficiency testing desk review survey was performed on 11/20/2025, the laboratory was found not in compliance with the following CONDITION LEVEL DEFICIENCIES D2016 - 42 C.F.R. 493.803 Condition: Successful [proficiency testing] participation; and D6000 - 42 C.F.R. 493.1403 Condition: Laboratories performing moderate complexity testing; laboratory director. D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) - 0155D and AAB-Medical Laboratory Evaluation records (2025-2 and 2025-3), the laboratory failed to successfully participate in a proficiency testing Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- program approved by HHS for each specialty, subspecialty and analyte or test in which the laboratory is certified under CLIA, the laboratory failed to successfully participate in the specialities of Routine Chemistry analytes - a. Carbon Dioxide - 0%, for 2025 testing events 2 & 3; b. Chloride - 0%, for 2025 testing events 2 & 3; c. Creatinine - 0%, for 2025 testing events 2 & 3; d. Glucose - 0%, for 2025 testing events 2 & 3; e. Potassium - 0%, for 2025 testing events 2 & 3; f. Sodium - 0%, for 2025 testing events 2 & 3; g. BUN - 0%, for 2025 testing events 2 & 3. D2096 ROUTINE CHEMISTRY CFR(s): 493.841(f) (f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 0155D Individual Laboratory Profile and AAB-Medical Laboratory Evualation report, the laboratory failed to achieve satisfactory performance for two of three consecutive events (2025-2 and 2025-3) for the analytes: Carbon Dioxide, Chloride, Creatinine, Glucose (non-waived), Potassium, Sodium, Blood Urea Nitrogen, Carbon Dioxide, Chloride, Creatinine, Glucose, Potassium, Sodium, and BUN. A review of the 2025 scores from AAB-Medical Laboratory Evaluation confirmed the above findings. D2097 ROUTINE CHEMISTRY CFR(s): 493.841(g) (g) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 0155D Individual Laboratory Profile and AAB-Medical Laboratory Evaluation report, the laboratory failed to achieve satisfactory performance for two of three consecutive events (2025-2 and 2025-3) for the specialty Routine Chemistry: The finding include: Routine Chemistry 0% - 2025 second and third testing events; A review of the 2025 scores from AAB-Medical Laboratory Evaluation report confirmed the above findings. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on a proficiency testing desk review of the CASPER 0155D report and AAB- -- 2 of 3 -- Medical Laboratory Evaluation records for 2025-2 and 2025-3 events, the laboratory director failed to provide overall management and direction of the laboratory services. Refer to D6016. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on a proficiency testing desk review of the CASPER 0155D report and AAB- Medical Laboratory Evaluation records for 2025-2 and 2025-3 events, the laboratory director failed to ensure successful participation in an HHS proficiency testing program. Refer to D2096 and D2097. -- 3 of 3 --

Summary Statement of Deficiencies D3005 FACILITIES CFR(s): 493.1101(a)(3) Molecular amplification procedures that are not contained in closed systems have a uni-directional workflow. This must include separate areas for specimen preparation, amplification and product detection, and, as applicable, reagent preparation. This STANDARD is not met as evidenced by: Based on direct observation of the facilities layout, observation of the of the laboratory's SARS-CoV-2 RNA (COVID-19) Polymerase Chain Reaction (PCR) testing, and interviews with the laboratory's technical supervisor (TS) and testing personnel (TP) on October 19, 2022 on its molecular amplification procedure; it was determined that the laboratory failed to ensure that the PCR procedures which are not contained in closed systems have a unidirectional flow with separate areas for specimen preparation, master mix and reagents preparation, amplification, and product detection. The findings included: 1. The laboratory performed PCR testing for the presumptive detection of SARS-CoV-2 using Thermofisher procedure and equipment. 2. During the laboratory tour on October 19, 2022, at approximately 11:30 a.m. the surveyor observed that processing of the specimens, preparation of reagents, and sample template addition were all performed in the same open area without unidirectional flow. 3. The TS and TP confirmed by interview on 10/19/2022 that the laboratory's molecular PCR testing for the presumptive detection of SARS-CoV-2 RNA was not set up in a unidirectional flow area. 4. Based on laboratory records, the laboratory performed and reported approximately 4,500 SARS-CoV-2 Real Time PCR molecular diagnostic tests annually. D3007 FACILITIES CFR(s): 493.1101(b) The laboratory must have appropriate and sufficient equipment, instruments, reagents, Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 4 -- materials, and supplies for the type and volume of testing it performs. This STANDARD is not met as evidenced by: Based on the surveyor's observation during the laboratory's tour, review of laboratory policies and procedures, and interviews with the technical supervisor (TS) and testing personnel (TP); it was determined that the laboratory failed to have a Biosafety Cabinet (BSC) when preparing reagents and control to use in the polymerase reaction (PCR) to detect SARS-CoV-2. Findings include: 1. The surveyor observed during the laboratory's tour testing personnel using an open bench table to prepare reagents such as master mix and controls used for the PCR detection of SARS-CoV-2. 2. The TS and TP affirmed by interview that the laboratory lacked a designated BSC for the preparation of PCR reagents and controls. 3. Based on the testing volume declaration the laboratory processed and reported approximately 4,5000 SARS-CoV-2 annually. D5421 ESTABLISHMENT AND VERIFICATION OF PERFORMANCE CFR(s): 493.1253(b)(1) Each laboratory that introduces an unmodified, FDA-cleared or approved test system must do the following before reporting patient test results: (1)(i) Demonstrate that it can obtain performance specifications comparable to those established by the manufacturer for the following performance characteristics: (1)(i)(A) Accuracy. (1)(i) (B) Precision. (1)(i)(C) Reportable range of test results for the test system. (1)(ii) Verify that the manufacturer's reference intervals (normal values) are appropriate for the laboratory's patient population. This STANDARD is not met as evidenced by: Based on the incomplete laboratory's verification of performance documentation for the high complexity testing SARS-CoV-2 (COVID-19) RNA detection by the Polymerase Chain Reaction (PCR), interviews with the laboratory's technical supervisor (TS) and the testing personnel (TP), and four (4) randomly selected patient test records for COVID-19 reviewed from 3/17/2021 and 7/27/2022; the laboratory failed to demonstrate that it established performance specifications comparable to those established by the manufacturer. The findings included: 1. The laboratory did not have any documentation to show for determination of PCR performance specifications for SARS-CoV-2 (COVID-19) RNA detection prior to reporting patient test results. The laboratory must be able to demonstrate that it can obtain performance specifications comparable to those established by the manufacturer for the following performance characteristics: (A) Accuracy (B) Precision (C) Reportable range of test results for the test system (D) Analytical sensitivity and (E) analytic specificity to include interfering substances. 2. The laboratory was unable to provide for review additional documents using patient samples to establish the performance specifications in 1. 3. The TS affirmed at the time of the survey on 10/19/2021 at approximately 11:15 a. m. that no documents could be retrieved to show that the SARS-CoV-2 RNA detection by PCR performance specifications were performed prior to reporting patient test results when the laboratory went live testing and reporting COVID-19 diagnostic tests. 4. Based on the estimated annual tests volumes reported on 10/19/2021; the laboratory performed and reported approximately 4,5000 SARS-CoV-2 PCR test. The precision and reliability of the reported results could not be assured. D6082 LABORATORY DIRECTOR RESPONSIBILITIES -- 2 of 4 -- CFR(s): 493.1445(e)(1) The laboratory director must ensure that testing systems developed and used for each of the tests performed in the laboratory provide quality laboratory services for all aspects of test performance, which includes the preanalytic, analytic, and postanalytic phases of testing. This STANDARD is not met as evidenced by: Based on the lack of the laboratory's verification of performance specification of the manufacturer for the detection of SARS-CoV-2, lack of unidirectional workflow when performing molecular amplification procedures that are not contained in a closed system, lack of a designated Biosafety Cabinet to minimize contamination when preparing reagents and controls used in the polymerase reaction, lack of delegation of responsibilities, and interviews with the laboratory's technical supervisor and testing personnel on October 19, 2022; it was determined that the laboratory director failed to ensure that several aspects of the preanalytic, analytic, and postanalytic phases of laboratory testing were monitored. See D3005, D3007, D5421, and D6107. D6086 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(3)(ii) The laboratory director must ensure that verification procedures used are adequate to determine the accuracy, precision, and other pertinent performance characteristics of the method. This STANDARD is not met as evidenced by: Based on the surveyor's review of the laboratory's policies & procedures, performance specifications validation and verification records, and interview with the laboratory's technical supervisor and testing personnel on October 19, 2022, at approximately 12: 15 p.m.; the laboratory failed to perform verification/validation of performance characteristics for the detection of SARS-CoV-2 by the Thermofisher procedure. The findings include See D5421. D6107 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(15) The laboratory director must specify, in writing, the responsibilities and duties of each consultant and each supervisor, as well as each person engaged in the performance of the preanalytic, analytic, and postanalytic phases of testing, that identifies which examinations and procedures each individual is authorized to perform, whether supervision is required for specimen processing, test performance or result reporting and whether supervisory or director review is required prior to reporting patient test results. This STANDARD is not met as evidenced by: Based on review of the laboratory's records of personnel training, competency evaluation, laboratory policies and procedures, random patient testing records, and interview with the laboratory 's technical supervisor (TS) and testing personnel (TP); the laboratory failed to provide records showing that the laboratory director (LD) has authorized, delegated, and approved lab personnel of any responsibilities and duties in -- 3 of 4 -- writing. The findings include: 1. The laboratory did not have any records of written delegation and authorization of responsibilities and duties by the LD for the laboratory's technical supervisor and testing personnel. 2. On October 19, 2022, at approximately 11:30 a.m. the TS and TP affirmed that the LD did not assign, delegated, and authorized in writing duties and responsibilities to the laboratory personnel including the TS and TP. 3. The laboratory testing declaration form, signed by the LD on October 29, 2022, stated that the laboratory performs 101,615 tests annually. -- 4 of 4 --

Summary Statement of Deficiencies D2000 ENROLLMENT AND TESTING OF SAMPLES CFR(s): 493.801 Each laboratory must enroll in a proficiency testing (PT) program that meets the criteria in subpart I of this part and is approved by HHS. The laboratory must enroll in an approved program or programs for each of the specialties and subspecialties for which it seeks certification. The laboratory must test the samples in the same manner as patients' specimens. For laboratories subject to 42 CFR part 493 published on March 14, 1990 (55 FR 9538) prior to September 1, 1992, the rules of this subpart are effective on September 1, 1992. For all other laboratories, the rules of this subpart are effective January 1, 1994. This CONDITION is not met as evidenced by: Based on the lack of proficiency testing enrollment/report and interviews with technical consultants (on 5/25/2018, at 10:00 A.M.), the laboratory failed to enroll in an approved proficiency testing program for the analyte creatinine. Findings include: a. The laboratory did not have proficiency enrollment/report for their creatinine test. b. Two technical consultants affirmed that the laboratory was not enrolled in a HHS approved proficiency testing program for the creatinine test. c. The laboratory receives approximately 50,000 urine samples/annually for toxicology testing. Each urine sample is testsed for creatinine and the result is reported, even though the laboratory failed to enroll in a HHS approved proficiency testing program. D5403 PROCEDURE MANUAL CFR(s): 493.1251(b) The procedure manual must include the following when applicable to the test procedure: (1) Requirements for patient preparation; specimen collection, labeling, storage, preservation, transportation, processing, and referral; and criteria for specimen acceptability and rejection as described in 493.1242. (2) Microscopic Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- examination, including the detection of inadequately prepared slides. (3) Step-by-step performance of the procedure, including test calculations and interpretation of results. (4) Preparation of slides, solutions, calibrators, controls, reagents, stains, and other materials used in testing. (5) Calibration and calibration verification procedures. (6) The reportable range for test results for the test system as established or verified in 493.1253. (7) Control procedures. (8)